Studies Show Amniotic Membrane Tissue Improve Foot, Ankle Outcomes (ODTMag)
Amniox Medical Inc., a TissueTech Inc. company, highlighted the results of two studies presented at the recent American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting. Dr. David Garras of Midwest Orthopaedic Consultants, an assistant professor at the University of Illinois at Chicago, and Dr. Ryan Scott, of the CORE Institute in Phoenix, Ariz., presented Plantar Fasciitis Treatment with Particulate Human Amniotic Membrane. Drs. Donald Covell, Bruce Cohen, Kent Ellington, Carroll Jones, Hodges Davis, and Robert Anderson, all from OrthoCarolina Foot and Ankle Institute in Charlotte, N.C., presented The Use of Cryo-Preserved Umbilical Cord Plus Amniotic Membrane Tissue in the Resection of Tarsal Coalition.
Garras’ findings involved 60 patients treated with ultrasound-guided injections of Clarix Flo particulate umbilical cord and amniotic membrane. An interim review of patients who had completed the full 18-week follow-up period demonstrated that all treatments showed statistically significant reduction of foot pain as well as an increase in foot ankle ability movement for both daily living and sports subscales. Garras concluded that Clarix Flo significantly decreased pain from baseline and improved overall functional recovery.
Plantar fasciitis is the most common cause of heel pain, affecting 1 million patients annually. Conservative therapies are ineffective in 10 to 15 percent of patients. Other available treatments including corticosteroids and surgery can carry risks such as plantar fascia rupture, biomechanical instability and post-operative pain.
To read the full feature, see it at ODTmag – Studies Show Amniotic Membrane Tissue Improve Foot, Ankle Outcomes